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γδ T Cell-Mediated immunity to 
Cytomegalovirus infection
Camille Khairallah, Julie Déchanet-Merville* and Myriam Capone*
Immunoconcept, CNRS UMR 5164, Bordeaux University, Bordeaux, France
γδ T lymphocytes are unconventional immune cells, which have both innate- and 
adaptive-like features allowing them to respond to a wide spectrum of pathogens. For 
many years, we and others have reported on the role of these cells in the immune 
response to human cytomegalovirus in transplant patients, pregnant women, neonates, 
immunodeficient children, and healthy people. Indeed, and as described for CD8+ T 
cells, CMV infection leaves a specific imprint on the γδ T cell compartment: (i) driving a 
long-lasting expansion of oligoclonal γδ T cells in the blood of seropositive individuals, 
(ii) inducing their differentiation into effector/memory cells expressing a TEMRA phenotype, 
and (iii) enhancing their antiviral effector functions (i.e., cytotoxicity and IFNγ production). 
Recently, two studies using murine CMV (MCMV) have corroborated and extended 
these observations. In particular, they have illustrated the ability of adoptively transferred 
MCMV-induced γδ T cells to protect immune-deficient mice against virus-induced death. 
In vivo, expansion of γδ T cells is associated with the clearance of CMV infection as well 
as with reduced cancer occurrence or leukemia relapse risk in kidney transplant patients 
and allogeneic stem cell recipients, respectively. Taken together, all these studies show 
that γδ T cells are important immune effectors against CMV and cancer, which are 
life-threatening diseases affecting transplant recipients. The ability of CMV-induced γδ T 
cells to act independently of other immune cells opens the door to the development of 
novel cellular immunotherapies that could be particularly beneficial for immunocompro-
mised transplant recipients.
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iNTRODUCTiON
Cytomegaloviruses (CMVs) belong to the betaherpesvirus family and infect different species includ-
ing rodents, non-human primates, and humans. The human cytomegalovirus (HCMV), also known 
as human herpesvirus 5 (HHV5), is an extremely widespread pathogen that infects from 30 to 90% 
of individuals. CMVs are highly species specific, having coevolved and adapted to their respective 
host. Thus, HCMV is unable to establish a productive infection in mice. Yet, human and murine 
CMV (MCMV) share many biological properties: (i) they present comparable structures and some 
viral proteins are homologous between human and mouse (1, 2); (ii) they show similar tissue tropism 
(3, 4); (iii) they induce similar pathologies in immunocompromised hosts (e.g., pneumonitis or 
hepatitis) (5–9), justifying MCMV infection of mice a widely used in vivo model to study CMV 
pathogenesis and antiviral immunity.
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Cytomegaloviruses are naturally transmitted through direct 
contact with body fluids such as saliva, urine, sperm, and breast 
milk. In immunocompetent hosts, CMV infection is usually 
asymptomatic, but some individuals may experience mild symp-
toms (10). However, the resolution of primary CMV infection 
does not result in complete elimination of the virus. Instead, 
CMV persists within its host in a latent form in hematopoietic 
and, likely, endothelial cells (11). Reactivation of viral gene 
expression occurs sporadically and might be initiated by chro-
matin remodeling (12) [for review on latency, see Ref. (13–15)]. 
The mechanism controlling the exit from CMV latency depends 
on both the differentiation status of the latently infected cells, and 
on the immune status of the host. Keeping CMV asymptomatic 
thus requires a robust and well-orchestrated immune response.
The immunosuppressive or hematoablative therapy applied 
in solid organ transplantation (SOT) or hematopoietic stem 
cell transplantation (HSCT) render patients susceptible to 
opportunistic pathogens, with CMV infection being the most 
common. CMV can cause either a viral syndrome (with fever, 
leukopenia) or a tissue-invasive disease (such as hepatitis, pneu-
monitis). Fortunately, the clinical effects of CMV infection have 
been greatly reduced by preemptive, prophylactic, and curative 
therapies, such as the development of CMV viremia detection 
(antigenemia and PCR) and of anti-CMV antivirals (ganciclovir, 
valganciclovir) (16). Nonetheless, CMV continues to be one of 
the leading causes of morbidity, due to the toxicities of antiviral 
drugs, to the emergence of antiviral resistance (17–19), to the 
“indirect effects” of CMV infection (20), and opportunistic 
infections (21, 22). Consequently, there is growing interest in 
evaluating cell-mediated immunity to improve the diagnosis and 
management of CMV infection.
Cell-mediated immunity to CMV is among the most robust 
ever documented. Before focusing on γδ T cells, we will provide a 
quick overview of the NK and CD8+ αβ T cell responses to CMV 
in humans and mice. These responses are depicted in Figures 1 
and 2.
CeLLULAR iMMUNiTY DURiNG ACUTe 
CMv iNFeCTiON iN iMMUNe-
COMPeTeNT MiCe
The mouse model of CMV infection has been useful to study the 
kinetics of immune effectors responses in organs, particularly in 
the liver, spleen, and lungs, which are important targets of CMV. 
Early post MCMV entry, phagocytes and dendritic cells (DCs) 
are activated through the recognition of viral products by toll-
like receptors (TLR) (23, 24) and the interferon-inducible protein 
AIM2, which binds double-stranded DNA (25). This leads to the 
release of type I interferons (IFNs) and inflammatory cytokines, 
among which are interleukin (IL)-12 and IL-18 (26–28). These 
mediators induce early IFNγ production and cytolysis by NK cells 
(29, 30) (Figure 1). Infection of mice with MCMV has provided 
direct evidence of the importance of this subset in CMV clearance 
and protection. In contrast to BALB/c mice, C57BL/6 mice are 
highly resistant to CMV, due to expression of Ly49H on 50% of 
NK cells, an activating receptor that recognizes the virally encoded 
m157 viral protein on the surface of infected cells (31–34). Over 
the first week of MCMV infection, Ly49H+ NK cells expand 
significantly in the liver and spleen, and begin expressing the 
inhibitory receptor KLRG1 (35–37). Establishment of primary 
CMV infection also drives DCs maturation. Presentation and/or 
cross-presentation of viral peptides to CD4+ and CD8+ αβ T cells 
induces their differentiation and effector function. According to a 
report by Schlub et al., the kinetics of NK and T cell proliferation 
during acute MCMV infection are concomitant and peak at day 
7; however, NK cell contraction after the peak is slower than that 
of T cells (38).
While the role of NK cells in early control of CMV was clearly 
evidenced in mice, CD3ϵ−/− mice succumbed to MCMV infec-
tion about 4 weeks after exposure. These results emphasize the 
importance of T cells in long-term control of MCMV. Studies in 
MCMV-infected, T-cell-deficient mice also revealed redundancy 
between T cell effectors [CD4+ versus CD8+ (39, 40), αβ versus 
γδ (41)], likely because they share important features for host 
protection.
CeLLULAR iMMUNiTY DURiNG ACUTe 
HCMv iNFeCTiON
The immune response against human CMV is, in its main steps, 
similar to the one observed in the mouse and is largely based on 
the triptych “Dendritic cells (DC)—NK cells—αβ T cells” (42, 43). 
HCMV entry occurs in concert with immune detection through 
TLR (44, 45) and nucleic acid sensors. The gamma-interferon 
inducible protein IFI16 was shown to play a crucial role as a viral 
DNA sensor in the first hours postinfection (46), but also acts 
as a repressor of viral gene transcription in the later stages (47). 
Recognition of viral products by TLR and DNA sensors induces 
the production of inflammatory cytokines and type I IFN by 
innate effectors, and subsequent activation of NK and αβ T cells. 
However, in healthy human subjects, the onset of primary HCMV 
infection typically goes unnoticed making it difficult to analyze 
the kinetics of immune effectors. The majority of studies regarding 
the early phases of the immune response to the virus have been 
carried out in HCMV-naive recipients (R−) of organ transplant 
from CMV-seropositive donors (D+). The situation is different 
from that of healthy individuals since transplant recipients are 
subjected to: (i) immunosuppressive drugs that cause lympho-
penia followed by homeostatic proliferation of lymphocytes, and 
(ii) antiviral therapies that influence the virus/lymphocytes ratio 
and subsequent activation of lymphocytes. One to two weeks 
after detection of HCMV viremia in blood, a NKG2C+ NK cell 
population preferentially expands and upregulates NKG2C and 
CD57 (48). NKG2C+ NK cells have been considered the human 
counterparts of murine Ly49H+ NK cells because of their reactiv-
ity against HCMV-infected cells and their memory function. 
However, in contrast to Ly49H, NKG2C recognize the self-ligand 
HLA-E (49) (Figures 1 and 2). HCMV-specific αβ T lymphocytes 
also appear in blood after the peak of CMV replication, with 
variable kinetics dependent on the patient and the immunosup-
pressive environment. The HCMV-specific αβ T cell responses 
that dominate during the acute phase are typified by classical 
expansion, contraction, and formation of long-term effector and 
central memory pools (50–52) [reviewed in Ref. (53)].
FiGURe 1 | Schematic representation of the primary and secondary response to CMv. Early during primary CMV infection, phagocytes and DCs are 
activated through TLRs and nucleic acid sensors by viral products and secrete pro-inflammatory cytokines (IFNαβ, IL-12, and IL-18) that induce NK cell and γδ T cell 
activation. Recognition of the protein m157 (C57BL/6 mouse) and HLA-E (human) or stress-induced ligands expressed by infected cells also stimulates NK cells and 
γδ T cells, respectively. This leads to the expansion of Ly49H+ (mouse) or NKG2C+ (human) NK cells and TEM (mouse) or CD16+ TEMRA (human) γδ T cells that persist 
over the long term. Activation of DCs leads to their maturation and migration to lymph nodes. Cross-presentation of viral peptides to naïve CD8+ αβ T cells induces 
their differentiation into TEM or TEMRA, expansion and acquisition of effector functions. Activated NK cells and αβ and γδ T cells can lyse and eliminate CMV-infected 
cells or control viral replication through secretion of anti-viral cytokines (e.g., IFNγ, TNFα). Despite the establishment of this immune response, CMV persists in its 
host. During viral reactivation episodes, CMV-induced immune cells react quickly to the presence of virions through the recognition of m157/HLA-E, stress antigens, 
or viral peptides. In addition, IFNγ secretion by CMV-elicited γδ T cells can be induced by CD16 interaction with Ig-opsonized viruses. The following color code has 
been used to distinguish mouse and human molecules or phenotypes: red color-mouse, blue color-human. Ag, antigen; CMV, cytomegalovirus; DC, dendritic cell; 
IFN, interferon, Ig, immunoglobulin; IL, interleukin; Mϕ, macrophage; NK, natural killer cell; TEM, effector memory T cell; TEMRA, CD45RA+ effector memory T cell; TLR, 
toll-like receptor.
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LATeNT CMv iNFeCTiON AND LONG-
TeRM ANTiviRAL CD8+ T CeLL 
ReSPONSe
During latent CMV infection in both humans and mice, a 
progressive and prolonged expansion of CMV-specific CD8+ 
αβ T cells has been observed, a phenomenon called “memory 
inflation” [reviewed in Ref. (54–56)]. Only a few epitopes drive 
memory inflation, derived from both early and late CMV gene 
products. Memory inflation was primary described in BALB/c 
mice by Holtappels et al., who showed an enrichment of CD62L− 
CD8+ T cells specific to IE1 (m123/pp89), during latent MCMV 
infection in the lungs (57). In C57BL/6 mice, four distinct pat-
terns were discerned, based on the epitope-specific CD8+ T cell 
responses during acute and persistent MCMV infection (58): 
(i) the responses to M45 and M57 displayed the classic kinetics 
of expansion, contraction, and stable memory, (ii) the response 
to m139 peaked at day 7, rapidly contracted, then underwent 
memory inflation, (iii) the response to M38 peaked at day 14 but 
underwent only limited contraction before reaching a long-term 
plateau, (iv) the responses to IE3 epitopes were above background 
until day 35, but became robust ≥4 months after infection. In sub-
sequent studies, the patterns exemplified by M45 and M38 were 
considered to be non-inflationary and inflationary, respectively. 
Interestingly, the C57BL/6 CD8+ T cell response to m139 is remi-
niscent to the one described for IE1/pp89 and m164 in BALB/c 
mice (59). Human inflationary CD8+ T cells recognize both 
IE1- and pp65-specific epitopes. In infants who mounted acute 
CD8 T cell responses, it was found that the IE1-specific response 
was always larger than the pp65-specific response by 1  year of 
age, regardless of which Ag was immunodominant upon initial 
infection (60). pp65-specific inflationary CD8+ T cells display an 
FiGURe 2 | Phenotypes of long-term cytomegalovirus (CMv)-induced NK, CD8+ αβ, and γδ T cells in humans and C57BL/6 mice. The main phenotypic 
and functional features of human (left panel) and mouse (right panel) CMV-induced NK and γδ T cells and CMV-specific CD8+ αβ T cells are listed. The surface 
markers commonly used to identify each population are emphasized in bold. As depicted, human and murine CMV-induced γδ T cells express an effector/memory 
phenotype closely related to CMV-specific CD8+ αβ T cells. In addition, human CMV-induced Vδ2− γδ T cells also shared some features (highlighted in red) with 
CMV-induced NK cells among which the expression of CD16 and CD158.
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oligoclonal but diverse αβ T cell receptor (TCR) repertoire that 
can be renewed upon antigen (Ag) reexposure (61).
In humans, inflationary CD8+ T cells use the longer CD45 
isoform (CD45RA), reminiscent of terminally differentiated 
cells. However, they show no evidence of T cell exhaustion and 
remain functional. Human and murine CMV-specific T cells 
exhibit several other features associated with T cell maturation 
(62, 63). These include downregulated expression of the corecep-
tors CD27 and CD28, and the expression of effector molecules 
such as perforin and granzyme (Figure  2). In C57BL/6 mice, 
M38-specific CD8+ T cells express an effector memory (EM) 
phenotype (CD62L−CCR7−CD27−), while chronic CD8+ T cells 
specific for M45 regained CD62L expression, typical of TCM 
(58). In comparison to long-lived CD8+ TCM, inflationary CD8+ 
T cells display higher expression of inhibitory receptors such 
as KLRG1 (63, 64) (Figure 2). According to mouse studies, the 
drivers of memory CD8+ T cell inflation are latently infected 
non-hematopoietic cells (65, 66). CD8+ T cells that dominate the 
chronic phase of MCMV infection are short lived and continu-
ously turned over (54, 67, 68). The likely source of inflationary 
CD8+ T cells is CD27+KLRG1− cells, because of their high prolif-
erative and self-renewal potential (69).
LATeNT CMv iNFeCTiON AND LONG-
TeRM ANTiviRAL NK CeLL ReSPONSe
Contrasting initial studies suggesting a short life span for NK 
cells, a set of recent studies describe long-term maintenance 
of memory-like NK cells in MCMV- and HCMV-infected 
hosts (70, 71). After adoptive transfer in DAP12- and Ly49H-
deficient mice, Ly49H+ cells undergo a robust clonal expansion 
followed by contraction and persistence for 70  days (72). This 
memory population has self-renewing capacity and is 10 times 
more potent in conferring protection against reinfection when 
compared to naïve cells. In mice, memory NK cells express high 
levels of KLRG1, low levels of CD27 (Figures 1 and 2), and are 
derived from KLRG1-negative progenitors with high prolifera-
tive potential (73). In humans, NKG2C+CD57+ NK cells express 
CD85j and can represent up to 70% of the total population of NK 
cells in HCMV-seropositive individuals. Their memory potential 
was suggested in HCMV-seropositive stem cell recipients who 
received a HCMV-seropositive (D+R+) or seronegative graft 
(D−R+). Importantly, NKG2C+ NK cells transplanted from D+ 
exhibit heightened function in response to a secondary CMV 
event compared with NKG2C+ NK cells from D−. Memory 
NKG2C+CD57+ NK cells display a mature phenotype, they 
are CD56dim, lack NKG2A, and express CD158b (48, 74, 75) 
(Figure 2).
More generally, during HSCT, the incidence of virus recur-
rence and disease is highest in the combination of an HCMV-
negative donor (D−) and an HCMV-positive recipient (R+) 
(D−R+ > D+R+ > D+R−), while just the opposite is true in the case 
of SOT (D+R− > D+R+ > D−R+). These risk assessments support 
the suggestions that (i) HCMV-reactivation occurs in latently 
infected tissues even in the case of HSCT and (ii) the develop-
ment of antiviral immune memory responses (of donors in case 
of HSCT, or recipients in case of SOT) is a good prognostic factor 
against CMV disease.
CD8+ T CeLL iMMUNOTHeRAPY OF CMv 
DiSeASe iN HSCT
The work by the Reddehase group in the mouse model of 
HSCT contributed substantially to provide a proof of concept 
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for CD8+ T-cell-based immunotherapy [for review, see Ref. 
(76–78)]. BALB/c mice received hematoablative, total-body γ 
irradiation followed by syngenic HSCT the same day as virus 
inoculation. This reproduced the timeframe of early-onset CMV 
disease in HSCT patients (1–4 months). In this model, infusion 
of MCMV-specific CD8+ T cells accelerated the resolution of 
primary infection and limited the establishment of viral latency 
(79). Moreover, MCMV was shown to infect bone marrow 
(BM) stromal cells and to interfere with T cell reconstitution 
after HSCT. CD8+ T cell immunotherapy thus tilts the balance 
in favor of viral control and gives a window for immune recon-
stitution. In the absence of adoptive T cells therapy, mortality 
can be prevented by transferring high doses of HSC into the 
host. By means of a recombinant virus in which four (BALB/c) 
immunodominant epitopes (IDEs) were functionally deleted, 
the Reddehase group elegantly showed that reconstitution of 
IDE-specific CD8+ T cells is not essential for antiviral control 
in infected HSCT hosts (80). Efficient protection in the absence 
of IDE was also evidenced in the CD8+ T cells adoptive transfer 
scenario (81).
Developing novel anti-HCMV therapies constitutes a major 
issue in transplantation. Adoptive transfer of HCMV-specific 
T cells from donors was shown to reduce the risk for HCMV 
disease in HSCT (82–86) and, more recently, SOT (87, 88). 
Multiple parameters that determine the efficacy of adoptive 
CD8+ T cells antiviral therapy are still under consideration, 
among which are (i) their antiviral function, (ii) their migratory 
capacity, (iii) their memory and self-renewing potential (77, 89), 
and (iv) their TCR avidity by monitoring dissociation (koff-rate) 
of truly monomeric peptide–MHC complexes bound to surface-
expressed TCRs (90).
Allogeneic HSCT can be used to treat otherwise incurable 
leukemia. Consequently, novel strategies in HSCT aim at reduc-
ing graft-versus-host disease, while maintaining immunological 
anti-leukemia and anti-infectious activity. Recent investigations 
aim at evaluating the potential use of NK cells (91, 92) and innate 
like effectors (93, 94) in this context.
γδ T CeLLS, ANTiGeN ReCOGNiTiON, 
AND eFFeCTOR FATe
γδ T lymphocytes contribute to both anti-infectious and antitu-
mor immune responses and display unique properties rendering 
them attractive targets for immunotherapy (95–98). Although 
they share important functions with αβ T cells, γδ T cells are 
distinct from αβ T cells most notably in antigen recognition and 
effector fate development. In contrast to αβ T cells, γδ T cells are 
not restricted by the major histocompatibility complex (MHC). 
The nature of ligands recognized by the γδ TCR is quite diverse 
including MHC-related and unrelated proteins, as well as low 
molecular weight non-peptidic ligands often found associated to 
presenting molecules [reviewed in Ref. (99–101)].
γδ T cells are the first T cells to appear in the fetal thymus. As 
the differentiation of αβ T cells progresses, the relative propor-
tion of γδ T cells decreases. In adult human peripheral blood, γδ 
T cells comprise approximately 4% of total CD3+ cells. γδ T cells 
home to similar peripheral sites as αβ T cells, in both lymphoid 
organs and tissues. They are generally found in lower proportions 
than αβ T cells, with the exception of epithelial sites where mouse 
γδ T cell subtypes home specifically during ontogeny and can 
reach 40% (intestine) and 100% (epidermis) of T lymphocytes. 
Most of γδ T cells found in organs from naïve mice display a 
functional polarization that is acquired during thymic selec-
tion. Expression of the costimulatory receptor CD27 segregates 
IL-17-producing (CD27−) and IFNγ-producing (CD27+) γδ 
T cells (102). CD27− γδ T cells are nonetheless endowed with 
functional plasticity and may produce IFNγ under local inflam-
matory conditions (103). In the periphery, functional orientation 
of γδ T cells depends on the microorganism encountered, with 
IFNγ- and IL-17-production dominating antiviral and antibacte-
rial responses, respectively (99).
γδ T lymphocytes are subdivided into subsets according to 
the nature of their TCR and cytokine production preferences 
[for review, see Ref. (99, 104–106)]. In mice, the fetal thymus 
gives rise consecutively to Vγ5+ (Vδ1+) and Vγ6+ (Vδ1+) γδ T 
cells, that home to the skin (Vγ5+ dendritic epidermal T cells 
or DETC), lungs, and uterus (Vγ6+), respectively. These cells 
are pre-committed to IFNγ (CD27+ Vγ5+) and IL-17 (CD27− 
Vγ6+) production. Before birth develop IFNγ-producing 
CD27+ NK1.1+ Vγ1+ (Vδ6.3+/6.4+) cells, as well CD27− IL17-
producing Vγ4+ (Vδ5+) cells (107). The (semi)-invariant 
nature of their TCR and response pattern contribute to the 
classification of these fetus-derived γδ T cells as “innate-like.” 
They show rapid responsiveness to innate stimuli such as 
upregulation of the expression of NKG2D ligand for DETC 
(108), IL-1β plus IL-23 for CD27− Vγ6+ cells (109), IL-18 
plus IL-12 for CD27+ NK1.1+ Vγ1+, and CD27+ CD45RBhigh 
Vγ4+ cells (110, 111). Innate-like γδ T cells are activated in 
the thymus and display an EM CD44+CD62L− phenotype, 
unlike “naïve” polyclonal CD44−CD62L+ Vγ1+ and Vγ4+ γδ 
T lymphocytes generated during adulthood. Naïve γδ T cells 
are mostly found in peripheral organs and blood. They are 
activated in the periphery after Ag exposure and display a 
functional plasticity. Other tissue-specific γδ T cell popula-
tions, including intraepithelial intestinal γδ T cells develop 
throughout adulthood. Intraepithelial intestinal γδ T cells 
express TCRs mainly composed of Vγ7.
In human, γδ T cells are divided in two subsets, the Vγ9+Vδ2+ 
T cells that are found predominantly in the blood, and all the 
other γδ T cells (collectively called Vδ2− γδ T cells, and mainly 
composed of Vδ1+ and Vδ3+ T cells) that are primarily located 
in tissues, particularly in epithelia. Only Vγ9+Vδ2+ T cells are 
activated through the TCR, and this is by small phosphorylated 
metabolites from the isoprenoid biosynthesis pathway (called 
phosphoantigens). Antigens recognized by Vδ2− γδ TCRs are 
largely unknown; however, a small subset of Vδ1 TCRs has 
been shown to recognize CD1d, both associated with lipids or 
not (112).
ReSPONSe OF γδ T CeLLS TO HCMv
The first evidence showing the mobilization of γδ T cells against 
HCMV was obtained in kidney transplant patients in our 
laboratory in 1999 (113). In those immunosuppressed patients, 
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HCMV infection leads to a strong increase (in proportion and 
number) of γδ T cells in the blood circulation, which persisted 
long term (114–116). Surprisingly, this expansion does not 
include the major γδ T cell subset present in the blood, namely, 
the Vγ9+Vδ2+ T lymphocytes. Indeed, HCMV-induced γδ T cells 
have been shown to express mainly the Vδ1 or the Vδ3 chain, and 
in some cases the Vδ5 chain. This rise of circulating γδ T cells 
correlated with the resolution of the infection, supporting their 
antiviral role (117).
Since these first reports, the expansion in blood and antiviral 
function of Vδ2− γδ T cells during HCMV infection has been 
shown in several other contexts of immunosuppression linked 
to organ and BM transplantation (118–120), in pregnant women 
(121, 122), and in children with a severe combined immunode-
ficiency (123, 124). Interestingly, this expansion is also observed 
in seropositive, healthy individuals illustrating that γδ T cells are 
not only mobilized in people with a defective immune response 
(119, 125). In otherwise healthy adults, HCMV was shown to 
prevent the decline of Vδ2− γδ T cells in the blood normally 
observed in the elderly (122, 126). Interestingly, Vermijlen’s 
team reported that, in addition to their role in adults, γδ T 
cells can participate in antiviral response early in life. In their 
report, they observed a γδ T cell response by the fetus during 
in utero HCMV infection (127). This response is qualitatively 
different from that observed in adults, since it involves Vδ2+ 
cells in addition to Vδ1+ and Vδ3+ cells. Fetal HCMV-specific 
γδ T lymphocytes are Vγ9− cells and express a public Vγ8+Vδ1+ 
TCR that has never been found in adults during HCMV infec-
tion (128). These differences show the capacity of HCMV to 
mobilize different repertoires of γδ T cells at different periods 
of life, highlighting the close relationship between this virus and 
γδ T cells.
eviDeNCiNG THe PROTeCTive  
ANTi-CMv ROLe OF γδ T CeLLS  
iN MiCe
Murine and human γδ T cells are closely related in many aspects 
including their predominant tissue localization (129), their abil-
ity to recognize non-MHC restricted viral antigens (130, 131), 
and their participation to the immune response against certain 
herpesviruses (132, 133). Infection of mice with MCMV thus 
appears as an interesting model to help decipher the role of γδ T 
cells in the immune response to CMV and extend the observa-
tions made in humans.
Using partially immunodeficient mice in the C57BL/6 
background, both our research team and Mach and Winkler 
have recently proven the protective antiviral function of γδ T 
cells during MCMV infection. Despite the reported importance 
of conventional αβ T cells in the control of MCMV (8, 78, 
134), we showed that murine γδ T lymphocytes are capable of 
protecting αβ T cell-deficient mice (i.e., TCRα−/− mice) against 
MCMV-induced organ damage and death (41). In contrast, 
CD3ϵ−/− mice (that lack both αβ and γδ T cells) died around 
1  month postinfection and show liver and lungs pathology, 
highlighting the absolute requirement of a T cell response in 
antiviral protection. The protective role of γδ T cells neither 
rely on B lymphocytes nor Ly49H+ NK cells, as CD4-depleted 
CD8−/− JHT mice (deficient for both CD8+ αβ T and B cells) 
survived upon challenge with a MCMV strain lacking the NK 
cell-activating m157 viral protein (135). In both TCRα−/− and 
CD4-depleted CD8−/− JHT mice, viral loads decreased about 
2 weeks postinfection, concomitantly with γδ T cell expansion 
in various CMV target organs including spleen, liver, and lungs 
(41, 135). The rise in γδ T cell number is at least partially due to 
the local proliferation of γδ T cells, as a substantial fraction of 
these cells incorporated BrdU after 14 days of infection (135). 
γδ T cell expansion was also evidenced in immunocompetent 
MCMV-infected hosts (136, 137), even though TCRδ−/− mice 
survived MCMV infection (41). The protective capacity of 
MCMV-induced γδ T cells isolated from both αβ-deficient and 
immunocompetent mice was confirmed by transfer into Rag−/− 
and Rag−/−γc−/− highly immunodeficient hosts that survived 
MCMV infection (41, 135). These results extend human studies 
and show that γδ T cells are an integral part of the immune 
response against CMV.
Although dispensable in immunocompetent hosts, γδ T cells 
could become essential in particular contexts of immunodefi-
ciency. Highlighting this assessment, immunodeficient children 
carrying a hypomorphic recombination activating gene (RAG)-1 
or a TCRα subunit constant gene (TRAC) mutation are relatively 
well protected against HCMV in spite of their deficiency in αβ  
T lymphocytes (123, 124, 138).
SiMiLARiTieS BeTweeN γδ AND αβ  
T CeLLS iN THe ReSPONSe TO HCMv
Human cytomegalovirus-induced Vδ2− γδ T lymphocytes and 
antiviral αβ T cells share common features evocative of an 
adaptive-like immune response. First, the rise of circulating γδ 
T cells is strictly correlated to HCMV infection, as conversely 
low γδ T cell percentages are correlated with other viral 
infections [herpes simplex virus (HSV), Epstein–Barr virus, 
influenza, and varicella-zoster] (114). Second, γδ and CD8+ 
αβ T cells follow similar expansion kinetics in infected kid-
ney transplant patients and pregnant women (121, 122, 139). 
Third, HCMV infection shapes the γδ TCR repertoire toward 
oligoclonality, even monoclonality in some extreme cases, 
while no repertoire restriction is observed in HSV-infected 
compared to seronegative individuals (125). Public HCMV-
specific αβ TCRs have been described in adults infected with 
the virus (140). Although this has not been reported in adults 
for γδ TCRs, it is noteworthy that neonatal infection induces an 
enrichment of a public Vγ8Vδ1-TCR found in all the infected 
neonates (127). Thus, it is conceivable that HCMV-expanded 
γδ T cells are selected in an antigen-dependent manner, as 
described for HCMV-specific CD8+ αβ T cells. Consistent with 
this, recognition of HCMV-infected cells by γδ T cells isolated 
from HCMV-infected individuals involves the γδ TCR (114, 
120, 141, 142).
Finally, HCMV-induced γδ T cells express an effector/memory 
TEMRA phenotype, defined as CD45RA+CD27−CD28−CD62L−CD
45RO−CCR7−CD38+HLA-DR+ (114, 122, 125, 139) and strictly 
similar to the one described for HCMV-specific CD8+ αβ T cells 
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(143, 144) (Figure 2). αβ and γδ T cells induced upon HCMV 
infection also share expression of regulatory receptors such as 
KLRG1 (64, 127) (Figure  2), probably involved in the control 
of their expansion. The memory potential of TEMRA Vδ2− γδ T 
cells is suggested by a faster recall response of these cells and 
better infection resolution in transplant patients experiencing 
a secondary (D+R+) versus primary (D+R−) CMV infection 
(125). Interestingly, long-term expansion of TEMRA Vδ2− γδ T 
cells evokes the inflationary phenomenon observed for HCMV-
specific CD8+ αβ T cells. An accentuation of HCMV-induced 
TEMRA γδ T cell proportion has been reported in elderly (122, 145) 
as previously shown for HCMV-specific αβ T cells [reviewed in 
Ref. (146–148)].
MOUSe AND HUMAN CMv-iNDUCeD  
γδ T CeLLS SHARe ADAPTive-LiKe 
FeATUReS
γδ T cells induced during MCMV infection share many char-
acteristics with HCMV-expanded Vδ2− γδ T cells. First, several 
subsets are involved in the response to CMV in both species {Vγ1, 
Vγ2, and Vγ4 in mice [nomenclature described in Ref. (149)] 
and Vδ1, Vδ3, and Vδ5 in humans} (41, 135, 136). Second, the 
expansion kinetics of γδ T cells in MCMV-infected mice and 
in HCMV-infected patients was similar to the one reported for 
conventional αβ T cells (58, 117, 150). Third, MCMV-induced 
Vγ1+ and Vγ4+ T cells acquired an EM phenotype that remained 
stable over time (41), as observed for MCMV-specific CD8+ αβ T 
cells (151), and reminiscent to HCMV-specific γδ and αβ T cells 
(Figure 2).
We hypothesize that a non-negligible part of MCMV-induced 
EM γδ T cells comes from naïve adaptive-like γδ T cells, mostly 
composed of Vγ1+ and Vγ4+ subsets and generated in the thy-
mus after birth. As opposed to innate-like γδ T cells, adaptive-
like γδ T cells display a more diverse TCR repertoire and have a 
delayed response due to their need for TCR-dependent priming 
to acquire their effector function (152, 153). The implication 
of these subsets in antiviral protection is further suggested by 
survival of BM transplant CD3ϵ−/− recipients that received γδ 
T cell precursors from TCRα−/− C57BL/6 mice (41). In this 
scenario, CMV infection occurs after immune reconstitution. 
In contrast, in the BALB/c mouse model described earlier, 
CMV infection is concomitant with HSCT in order to mirror 
early CMV reactivation posttransplantation. In these settings, 
depletion of CD8+ T cells during immune reconstitution (days 
7 and 14 postinfection) was lethal [reviewed in Ref. (78)]. 
Reconstitution of sufficient numbers of protective γδ T cells (and 
of other immune subsets) might take too long to counteract the 
spread of the virus. It would be interesting to test whether this 
holds true regardless of the mouse genetic background, since 
C57BL/6 and BALB/c mice display strain-specific immunity to 
CMV. Dispensability of T/NK cells was evidenced in adoptive 
transfer experiments using MCMV-primed γδ T cells. Thus, 
adoptive transfer of γδ T cells isolated from 6 weeks-infected 
CD8−/− JHT donors into Rag−/− mice confers long-term pro-
tection against MCMV (135). Along the same line, γδ T cells 
isolated from 2 weeks-infected TCRα−/− or wild-type C57BL/6 
mice protected Rag−/−γc−/− recipients against MCMV-induced 
death, whereas γδ T cells isolated from naïve mice failed to 
provide protection (41). Thus, effector and memory γδ T cells 
appear to be interesting candidate for adoptive cell transfer 
therapy against CMV.
In humans, Appay and colleagues interestingly analyzed γδ T 
cells in young adults (18–26 years old) who were thymectomized 
shortly after birth for cardiac surgery (122). This situation allows 
for the evaluation of the role of the post-birth thymus in the 
production of T cells responding to CMV. In contrast to control 
donors, no expansion of Vδ2− γδ T cells could be observed in 
thymectomized patients. This setting is to our knowledge the only 
physiopathological situation in which HCMV is not associated 
with Vδ2− γδ T cell expansion. This result strongly suggests that 
γδ T cells able to respond to HCMV are mainly produced in the 
thymus after birth. This is also consistent with the observation 
that HCMV infection in adults does not lead to the expansion of 
the public innate-like Vγ8Vδ1 TCR found in all HCMV-infected 
neonates (128).
Determining whether and which Ags are involved in γδ T cell 
expansion and activation requires further study and considera-
tion. In contrast to long-term HCMV-induced Vδ2− γδ T cells 
that display a restricted TCRδ repertoire (114, 119), the CDR3γ1 
and γ4 length repertoire of murine γδ T cells was equivalent at 
14  days in both infected and uninfected TCRα−/− mice (41). 
Yet, some Vγ1 and Vγ2 T cell clones were enriched 28  days 
postinfection (135), while the TCRγ4 cells repertoire appeared 
oligoclonal even in naïve mice with no clear difference after 
infection (41, 135).
SiMiLARiTieS BeTweeN γδ T AND NK 
CeLLS iN THe ReSPONSe TO CMv
Despite shared features with αβ T cells, the function of γδ T 
cells responding to CMV cannot be considered as “merely” 
redundant to αβ T cells. In contrast to HCMV-specific αβ T 
cells, Vδ2− γδ T cells express a panel of activating NK recep-
tors, among which is the low affinity receptor for the constant 
fragment of IgG: CD16, which allows γδ T cells to recognize IgG-
opsonized virus and induces the production of IFNγ without any 
prior TCR activation (Figures  1 and 2) (154). CD16 was also 
detected on MCMV-induced γδ T cells; moreover, MCMV and 
HCMV-induced γδ cells express the NKG2D (135); however, 
a role of this activating receptor in the recognition of HCMV-
infected cells by Vδ2− γδ T cells was ruled out (141). This is 
not surprising considering the evasion mechanisms developed 
by CMV to inhibit NKG2D ligand [MIC and UL16 binding 
protein (ULBP)] expression. γδ T cells that are selected in vivo 
by CMV and that undergo expansion, probably do not require 
NKG2D engagement to be stimulated. Conversely, neonate γδ 
T cells expanded during in  utero CMV infection overexpress 
CD94 and NKG2C, which may be a response to the induction of 
HLA-E expression on HCMV-infected cells (127, 155). Vδ2− γδ 
T cells from HCMV-infected transplant recipients or neonates 
also overexpress CD85j and diverse CD158 receptors when 
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compared to both uninfected patients and HCMV-specific αβ T 
cells (Figure 2) (125, 139, 141). This high expression of inhibi-
tory HLA-I receptors is probably important to regulate Vδ2− γδ 
T cells prone to self-reactivity (see below), in a way similar to NK 
cell regulation. Consequently, the well-known evasion process 
developed by CMV consisting of MHC downregulation is prob-
ably an important trigger for the γδ T cell response to CMV 
infection. Another common feature between NK and Vδ2− γδ T 
cells is the recognition of activating, stress-induced self-antigens 
(153). We have shown that HCMV-induced γδ T cells display 
a TCR-dependent dual reactivity against HCMV-infected cells 
and some tumor cells (141), which has been confirmed by 
another team (120). This dual reactivity relies on the recognition 
of stress-induced membrane self-antigens expressed on both 
HCMV-infected and cancer cells (142). This is reminiscent of the 
recognition of self-antigens on tumor cells or infected cells by 
NK cells, such as B7H6 recognized by NKp30 (156) or vimentin 
recognized by NKp46 (157).
HOw DO γδ T CeLLS CONTROL CMv 
iNFeCTiON?
As documented below, CMV-induced γδ T cells are capable of (i) 
IFNγ and TNFα production that may synergize to inhibit CMV 
replication (158) and (ii) CMV-infected cell killing that may 
participate to CMV clearance (Figure 1).
In humans, Vδ2− γδ T cell clones and lines isolated from 
peripheral blood of HCMV+ transplant recipients recognize 
HCMV-infected cells through their TCR. This leads to (i) the 
production of antiviral cytokines among which are TNFα and 
IFNγ, (ii) the killing of HCMV-infected cells, and (iii) the control 
of virus propagation in vitro (141). Similarly, Vγ8+Vδ1+ γδ T cell 
clones from HCMV-infected neonates exhibit IFNγ production 
in vitro when cultured with HCMV-infected cells (127). Vδ2− γδ 
T cells can also use CD16 to recognize HCMV virions coated with 
anti-CMV antibodies and produce IFNγ that limit viral multipli-
cation in vitro (154). Furthermore, HCMV-infected cells express 
caspase-1 inflammasomes and release IL-18. Engagement of the 
TCR on Vδ2− γδ T cells controlled the direct innate immune 
sensing of IL-18, which enhanced cytotoxicity and IFNγ produc-
tion by γδ T cells (159).
In mice, we performed ex vivo analysis (without prior stimula-
tion) of IFNγ production and CD107a expression by γδ T cells 
isolated from organs during the course of MCMV infection in 
TCRα−/− mice. The proportions of IFNγ+ and CD107a+ cells 
within γδ lymphocytes populations peaked at day 3 (IFNγ) and 
7 (CD107a), then decreased until day 14 (41). Early production 
of IFNγ by γδ T cells was also evidenced in C57BL/6 mice (136) 
and is consistent with their capacity to rapidly sense and react 
against cellular dysregulation (108, 160). In αβ-T cell competent 
hosts, early production of IFNγ by γδ and NK cells may overrule 
the inhibitory function of viral proteins that interfere with MHC 
class I expression and enhance the antiviral efficiency of CD8+  
T cells (161).
In TCRα−/− infected mice, similar kinetics were observed 
when analyzing IFNγ-producing and cytotoxic NK cells (41). 
However, the latter largely outnumbered IFNγ-producing and 
cytotoxic effector γδ T cells, in accordance with the important 
role of NK cells in early MCMV control (32). Efficient control 
of viral load was observed upon γδ T cell transfer in recipient 
Rag−/− mice treated with either anti-IFNγ or anti-IL-17 mAb 
(135). These results suggest that γδ T cell protective function 
does not involve IFNγ nor IL-17. However, further investiga-
tions are required to rule out their involvement in γδ T cell 
antiviral activity, because of the difficulty to completely inhibit 
cytokines with antibodies. Finally, Winkler’s group showed that 
γδ T cells isolated from 4 weeks-infected CD8−/− JHT mice killed 
MCMV-infected mouse embryonic fibroblasts (MEFs), but not 
uninfected MEFs (135).
Altogether, these results suggest a biphasic response of γδ T 
lymphocytes during CMV infection: (i) an early phase mobiliz-
ing IFNγ-producing and cytotoxic γδ T cells, which act together 
with other immune effectors (particularly NK cells) for rapid and 
efficient viral control and (ii) the generation of EM γδ T cells 
able to protect the host in the long-term and whose effector and 
memory functions are under consideration in our laboratory.
CLiNiCAL iNTeReST OF γδ T CeLL 
ReSPONSe TO CMv
Different specificities make γδ T cells particularly tailored to 
respond to CMV. As mentioned above, the antigen specificity of 
γδ T cells is highly different from that of αβ T cells. We recently 
identified EPCR as a TCR ligand of a HCMV-expanded γδ T cell 
clone expressing a Vγ4Vδ5 TCR (142). Although EPCR presents 
some homologies with antigen-presenting molecules, i.e., MHC 
class I and CD1 molecules, its recognition is not dependent on 
lipid but rather relies on the direct binding of the TCR to EPCR 
itself. By contrast to MHC class I, HCMV infection of fibroblasts 
or endothelial cells does not affect EPCR expression (142). This 
suggests that γδ T cells are not impaired by the classical immune 
evasion processes developed by CMV to escape αβ T cells. It 
remains however to be tested whether host-virus co-evolution 
led to other γδ T cell-specific escape mechanisms. Localization 
of Vδ2− γδ T cells in intestinal and lung epithelia and in the liver, 
i.e., sites of CMV entry and/or multiplication, is also probably 
important for their implication in the response to CMV.
Consequently, γδ T cells represent an interesting clinical 
target in the context of CMV infection. First, quantifying 
Vδ2− γδ T cells in the blood is an easy assay to detect immune 
response to CMV in patients. Provided it is proven as reliable 
as CMV-specific αβ T cell detection, evidencing Vδ2− γδ T cell 
expansion is more convenient and cheaper (one step direct 
staining in whole blood with only anti-CD3, anti-pan-delta, 
and anti-Vδ2 antibodies) than the detection of CMV-specific 
αβ T cells using MHC tetramers or activation by viral peptides. 
We recently revealed the prognostic value of their expansion to 
predict CMV-relapse in patient suffering from a first infection 
episode and treated by valganciclovir (162, 163). Second, their 
antiviral functions supported the development of new graft 
preparation procedures in stem cell transplantation. In recent 
clinical trials, depletion of whole T cells from the graft to avoid 
graft-versus-host disease was replaced by αβ T cell depletion 
(164). The goal of such procedure is to keep γδ T cells within 
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the graft to prevent CMV infection and promote graft versus 
leukemia/lymphoma effect because of the γδ T cell reactivity 
against tumor cells (165), for review, see Ref. (166). Third, the 
ongoing identification of stress-induced self-antigens expressed 
by CMV-infected cells could pave the way toward the develop-
ment of vaccination strategies using these antigens, in a similar 
way as what has been done in clinical trials using phosphoan-
tigens activating Vγ9Vδ2 T cells (167). Fourth, development of 
cell therapy based on γδ T cells activated in vitro and reinjected 
in patients has been proposed in cancer (96, 168), but could also 
prove useful in CMV infection.
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